Perrigo’s Pending OTC Launches Promising But Pandemic Precludes Pumping Guidance
A diclofenac topical analgesic is first, likely followed by a line extension for its Prevacid 24HR PPI brand. Perrigo also plans to introduce natural-based products that “leverage our expertise in Europe."
You may also be interested in...
US Q2 Consumer Health Earnings Preview: Will More Favorable Year-Ago Comparisons Help?
April-June sales of OTC drugs, supplements and personal care products likely will show at least notable and potentially strong increases from year-ago period when consumers slowed spending after splurging during 2020 Q1 as novel coronavirus pandemic sent shockwaves through the marketplace.
Safety First For Perrigo In CBD Market; ‘Long-Term’ Play Starts With Clinical Trials
Perrigo’s clinical trials on CBD likely will take years before resulting products help bring order to the market. During earnings presentation, CEO Murray Kessler says the trials aren’t intended to establish claims for CBD but are more a long-term effort to provide data to FDA.
Perrigo Moves Closer To Exclusive Consumer Focus With UK Rx Generics Business Sale
Perrigo’s ambitions to become a consumer-focused company are a step closer after the firm announced an immediate sale of a ‘non-core’ asset.